An individualized immune scoring system integrating multi-omics data will advance precision classification and treatment of CRC (206), positioning the “microbiota–IFN–PCD” axis as a novel target for clinical translation and drug development. This evidence concerns the gene IFNA1 and colorectal carcinoma.